Loading...
•
Sep 30, 2020
BioNano Q3 2020 Earnings Report
Bionano Genomics reported financial results for the third quarter of 2020.
Key Takeaways
Bionano Genomics reported a total revenue of $2.2 million for Q3 2020, which is up 86% sequentially from the prior quarter, but down 33.7% compared to the same period in 2019. The company's cash and cash equivalents were $18.9 million as of September 30, 2020, compared to $17.3 million at the end of 2019. The company also acquired Lineagen, which added $0.4 million to revenue.
Total revenue was $2.2 million, up 86% sequentially from the prior quarter.
Lineagen acquisition added $0.4 million to Q3 revenue.
Cost of revenue decreased by 38.5% to $1.5 million compared to the same period in 2019.
Cash and cash equivalents were $18.9 million as of September 30, 2020.
Revenue by Segment
Forward Guidance
No forward guidance was provided in the earnings report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...